3 Reasons to invest
Using our robust and scalable delivery platform, we develop immunotherapeutic agents that activate and direct T cells against cancer, and complement the activity of other immuno-modulating agents.
DPX-Survivac is currently being evaluated in multiple clinical trials in combination with other advanced immunotherapy agents, including checkpoint inhibitors, in collaboration with Merck. These include two triple combination trials in advanced ovarian cancer, one of our main areas of therapeutic focus.
In addition to being a widely recognized tumor-associated antigen (TAA), survivin also plays an important role in the dysregulated cell apoptosis and metastasis that are the hallmarks of cancer.
- 2019-11-08 12:17:03 UTC
- 2019-11-06 14:38:15 UTC
- 2019-11-05 13:08:10 UTC
- 2019-10-30 11:28:00 UTCIMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel c...
- 2019-10-29 11:28:05 UTCIMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical...
- 2019-10-16 14:21:19 UTC
- 2019-10-11 12:23:58 UTCIMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that ...
- 2019-09-30 10:25:17 UTC
- 2019-09-23 11:18:01 UTC
- 2019-09-04 19:06:44 UTCDARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a cli...